GetTopicDetailResponse(id=8342553e7b, topicName=CXCL12, introduction=CXCL12, content=null, image=null, comments=1, allHits=1649, url=https://h5.medsci.cn/topic?id=5537, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=70895, tagList=[TagDto(tagId=70895, tagName=CXCL12)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2265197, encodeId=94ab226519e00, content=<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝細胞癌#</a> <a href='/topic/show?id=8342553e7b' target=_blank style='color:#2F92EE;'>#CXCL12#</a>, objectTitle=Nat Commun：杭州醫(yī)學(xué)院徐驍?shù)葓F隊研究證明了CXCL12通過CXCR4促進XRCC5來維持肝癌細胞的干性, objectType=article, longId=877370, objectId=ae458e7370fd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867576310_4754896.jpeg, objectUrl=/article/show_article.do?id=ae458e7370fd, replyNumber=0, likeNumber=30, createdTime=2025-05-15, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ae458e7370fd, moduleTitle=Nat Commun：杭州醫(yī)學(xué)院徐驍?shù)葓F隊研究證明了CXCL12通過CXCR4促進XRCC5來維持肝癌細胞的干性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ae458e7370fd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2260033, encodeId=f4eb2260033d4, content=<a href='/topic/show?id=8342553e7b' target=_blank style='color:#2F92EE;'>#CXCL12#</a> <a href='/topic/show?id=b55889e960b' target=_blank style='color:#2F92EE;'>#血管重建#</a> <a href='/topic/show?id=a077125944f6' target=_blank style='color:#2F92EE;'>#后降支動脈#</a>, objectTitle=Cell：新研究發(fā)現(xiàn)基因CXCL12與后降支動脈的形成有關(guān), objectType=article, longId=871456, objectId=a9ec8e14563d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20250411/1744325746607_2185383.png, objectUrl=/article/show_article.do?id=a9ec8e14563d, replyNumber=0, likeNumber=22, createdTime=2025-04-11, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2255209, encodeId=083e2255209fe, content=<a href='/topic/show?id=601f3083e98' target=_blank style='color:#2F92EE;'>#冠狀動脈#</a> <a href='/topic/show?id=8342553e7b' target=_blank style='color:#2F92EE;'>#CXCL12#</a>, objectTitle=Cell：你的心臟是左派還是右派？心臟血管的"左右抉擇", objectType=article, longId=866249, objectId=fdef866249f7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250220/1740102008933_4754896.jpg, objectUrl=/article/show_article.do?id=fdef866249f7, replyNumber=0, likeNumber=37, createdTime=2025-03-08, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=fdef866249f7, moduleTitle=Cell：你的心臟是左派還是右派？心臟血管的"左右抉擇", moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fdef866249f7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2105178, encodeId=642921051e81b, content=使用<a href='/topic/show?id=35ce1050e686' target=_blank style='color:#2F92EE;'>#格列汀類#</a>降低<a href='/topic/show?id=c56f43e89eb' target=_blank style='color:#2F92EE;'>#大皰性類天皰瘡#</a>和<a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a>患者的<a href='/topic/show?id=3b941608085' target=_blank style='color:#2F92EE;'>#SDF-1#</a>/<a href='/topic/show?id=8342553e7b' target=_blank style='color:#2F92EE;'>#CXCL12#</a>水平，但不增加<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>抗<a href='/topic/show?id=3a54363e13' target=_blank style='color:#2F92EE;'>#BP180#</a>的<a href='/topic/show?id=39998636197' target=_blank style='color:#2F92EE;'>#自身抗體#</a>水平。<a href='/topic/show?id=2c679051240' target=_blank style='color:#2F92EE;'>#西格列汀#</a>，這項研究有意思, objectTitle=Front Immunol：使用格列汀降低大皰性類天皰瘡和2型糖尿病患者的SDF-1/CXCL12水平，但不增加糖尿病患者抗BP180的自身抗體, objectType=article, longId=739441, objectId=f6efe39441ca, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/114.jpg, objectUrl=/article/show_article.do?id=f6efe39441ca, replyNumber=0, likeNumber=256, createdTime=2022-12-10, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f6efe39441ca, moduleTitle=Front Immunol：使用格列汀降低大皰性類天皰瘡和2型糖尿病患者的SDF-1/CXCL12水平，但不增加糖尿病患者抗BP180的自身抗體, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f6efe39441ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
